Author Correction: Every step of the way: integrins in cancer progression and metastasis.
Where this comes from
- Record sourced from PubMed, PMID 30705430.
- Also identified by DOI 10.1038/s41568-019-0112-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the originally published article, pertuzumab was incorrectly described as an anti-PI3K therapy in the section 'Integrins in anticancer therapy'. The sentence should read 'In mouse mammary tumour models, increased collagen levels and increased β1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies164.' This has now been corrected in all versions of the original article.